Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

221.21 -2.92 (-1.30%)

Streaming Delayed Price Updated: 11:55 AM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about AbbVie

< Previous 1 2 3 4 5 6 7 8 9 Next >

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

February 12, 2025

From Xilio Therapeutics, Inc.; AbbVie Inc.

Via GlobeNewswire

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

December 26, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END

Via FinancialNewsMedia

Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook

December 26, 2024

From FN Media Group LLC

Via GlobeNewswire

Best Pharma Stocks for Long-Term Investors: Growth and Dividends

October 14, 2024

Big pharmaceutical firms may lack the potential for rally driven by a breakout drug like small biotechs, but stability and steady growth remain attractive.

Via MarketBeat

AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential

October 11, 2024

AbbVie is tracking for a new high that may be reached before the end of the year. Acquisitions fuel the growth outlook, cash flow and capital returns.

Via MarketBeat

Topics Intellectual Property

Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket

October 04, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition

October 01, 2024

Via Investor Brand Network

Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition

October 01, 2024

EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

AbbVie Stock Post Humira is Still an Attractive Stock to Hold

September 04, 2024

AbbVie's strategic diversification and strong financial position make it possible to sustain growth despite the perceived “Humira cliff.”

Via MarketBeat

Topics Intellectual Property

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

September 04, 2024

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

September 04, 2024

From FN Media Group LLC

Via GlobeNewswire

3 Best Growth Stocks to Own for the Next 10 Years

August 28, 2024

When in doubt, zoom out; these three growth stocks have a history of strong performance that is likely to continue for the next 10 years

Via MarketBeat

Topics Economy

Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon

August 16, 2024

These three stocks have a long history of increasing their dividends and are likely to benefit from sector rotation on expectations of lower interest rates

Via MarketBeat

Topics Artificial Intelligence Economy

As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032

August 09, 2024

EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment

August 06, 2024

New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves...

Via PressReach

AbbVie Analysts Lead the Stock Higher as Humira Worries Recede

July 30, 2024

AbbVie had a solid quarter, accelerating growth and giving positive guidance that has analysts lifting their price targets and the stock advancing.

Via MarketBeat

Topics Earnings Intellectual Property

Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity

July 30, 2024

Merck stock is down more than 4% after lowering its 2024 earnings outlook, but if you look beyond the headline numbers, this could be a chance to buy the dip

Via MarketBeat

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

July 28, 2024

From Alector, Inc.

Via GlobeNewswire

Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected

July 25, 2024

EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:AXSM) EQNX::TICKER_END

Via FinancialNewsMedia

Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected

July 25, 2024

From FN Media Group LLC

Via GlobeNewswire

Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem

July 10, 2024

Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024

Via MarketBeat

MarketBeat Week in Review – 7/1 - 7/5

July 06, 2024

The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season

Via MarketBeat

Topics Economy

AbbVie Stock: A Perfect Dip for Investors to Buy

July 03, 2024

ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors

Via MarketBeat

Topics ETFs

Investing in Biotech: High Risk for a Potentially High Reward

June 06, 2024

Biotech is an exciting and promising area, and investors with some patience, the stomach for volatility, and a high risk tolerance can potentially benefit.

Via MarketBeat

2 Generic Drug Makers With Growing Runways

May 31, 2024

Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out.

Via MarketBeat

Topics Intellectual Property

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

May 24, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

AbbVie Tracking for New Highs in 2024

May 07, 2024

Future Dividend King AbbVie is tracking for new highs as the shift away from Humira-based business gains momentum with new treatments and acquisitions.

Via MarketBeat

Topics Earnings

MarketBeat Week in Review – 4/29 - 5/3

May 04, 2024

Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024

Via MarketBeat

Topics Economy Stocks

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

May 24, 2024

From FN Media Group LLC

Via GlobeNewswire

Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher

April 30, 2024

After falling nearly 6% based on concerns about Humira sales, AbbVie stock is recovering, and bullish analyst sentiment is likely to push the stock higher

Via MarketBeat

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.